IL-23单抗-话题@MedSci

#IL-23单抗#

17篇内容 | 694人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1755728, encodeId=c3451e55728e7, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率, objectType=article, longId=202204, objectId=7085202204a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7085202204a8, replyNumber=0, likeNumber=36, createdTime=2020-11-24, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7085202204a8, moduleTitle=III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7085202204a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755724, encodeId=eb091e55724f2, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, objectType=article, longId=195839, objectId=0f4c19583900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f4c19583900, replyNumber=0, likeNumber=44, createdTime=2021-01-09, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f4c19583900, moduleTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f4c19583900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755726, encodeId=19531e55726db, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, objectType=article, longId=197732, objectId=5be919e73267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5be919e73267, replyNumber=0, likeNumber=41, createdTime=2021-06-01, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5be919e73267, moduleTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5be919e73267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755727, encodeId=f8901e55727f8, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, objectType=article, longId=198548, objectId=231019854869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=231019854869, replyNumber=0, likeNumber=32, createdTime=2021-07-04, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=231019854869, moduleTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=231019854869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755723, encodeId=d9a31e557239b, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎, objectType=article, longId=193135, objectId=1689193135a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1689193135a7, replyNumber=0, likeNumber=50, createdTime=2021-03-29, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1689193135a7, moduleTitle=英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1689193135a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755721, encodeId=4b1e1e55721a5, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx, objectType=article, longId=186385, objectId=ced718638553, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced718638553, replyNumber=0, likeNumber=44, createdTime=2020-11-28, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced718638553, moduleTitle=头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced718638553)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755725, encodeId=fb6c1e557257c, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究, objectType=article, longId=196588, objectId=da7919658856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da7919658856, replyNumber=0, likeNumber=33, createdTime=2021-04-05, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da7919658856, moduleTitle=由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da7919658856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755720, encodeId=43c91e55720f9, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=强生向欧洲药品管理局提交申请，寻求扩大其IL-23单抗Tremfya用于治疗银屑病关节炎, objectType=article, longId=181828, objectId=a684181828c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a684181828c3, replyNumber=0, likeNumber=34, createdTime=2019-10-28, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a684181828c3, moduleTitle=强生向欧洲药品管理局提交申请，寻求扩大其IL-23单抗Tremfya用于治疗银屑病关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a684181828c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755717, encodeId=33aa1e557172c, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效, objectType=article, longId=177388, objectId=8ab51e73889d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ab51e73889d, replyNumber=0, likeNumber=30, createdTime=2020-05-03, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ab51e73889d, moduleTitle=Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ab51e73889d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755719, encodeId=76091e557197e, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎, objectType=article, longId=181708, objectId=3487181e0866, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3487181e0866, replyNumber=0, likeNumber=35, createdTime=2019-12-13, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3487181e0866, moduleTitle=强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3487181e0866)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755716, encodeId=50e31e5571681, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病, objectType=article, longId=175399, objectId=02b91e539906, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02b91e539906, replyNumber=0, likeNumber=39, createdTime=2020-05-27, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02b91e539906, moduleTitle=NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02b91e539906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755718, encodeId=ac851e557181e, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, objectType=article, longId=180571, objectId=711e1805e121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=711e1805e121, replyNumber=0, likeNumber=31, createdTime=2020-01-24, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=711e1805e121, moduleTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=711e1805e121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755722, encodeId=d7631e55722f3, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, objectType=article, longId=188168, objectId=b557188168d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b557188168d1, replyNumber=0, likeNumber=33, createdTime=2020-03-06, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b557188168d1, moduleTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b557188168d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755715, encodeId=edb11e5571535, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, objectType=article, longId=161542, objectId=b41f1615426c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b41f1615426c, replyNumber=0, likeNumber=38, createdTime=2020-01-26, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b41f1615426c, moduleTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b41f1615426c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755714, encodeId=b79d1e557149a, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=MorphoSys宣布开始3期试验（PROTOSTAR）评估IL-23单抗Guselkumab对银屑病儿童患者的疗效, objectType=article, longId=149686, objectId=d1891496860a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1891496860a, replyNumber=0, likeNumber=40, createdTime=2018-09-26, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1891496860a, moduleTitle=MorphoSys宣布开始3期试验（PROTOSTAR）评估IL-23单抗Guselkumab对银屑病儿童患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1891496860a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755712, encodeId=3cde1e5571236, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, objectType=article, longId=148645, objectId=6dae148645a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dae148645a9, replyNumber=0, likeNumber=29, createdTime=2018-11-16, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dae148645a9, moduleTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dae148645a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755713, encodeId=7ac11e5571364, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, objectTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, objectType=article, longId=149073, objectId=52291490e33c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52291490e33c, replyNumber=0, likeNumber=40, createdTime=2019-04-04, rootId=0, userName=achengzhao, userId=a34037012693, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52291490e33c, moduleTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52291490e33c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IL-23单抗

2020-05-29

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率

2020-11-24

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab

2021-01-09

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx

2021-06-01

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者

2021-07-04

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎

2021-03-29

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx

2020-11-28

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究

2021-04-05

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

强生向欧洲药品管理局提交申请，寻求扩大其IL-23单抗Tremfya用于治疗银屑病关节炎

2019-10-28

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效

2020-05-03

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎

2019-12-13

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病

2020-05-27

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率

2020-01-24

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果

2020-03-06

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价

2020-01-26

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

MorphoSys宣布开始3期试验（PROTOSTAR）评估IL-23单抗Guselkumab对银屑病儿童患者的疗效

2018-09-26

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效

2018-11-16

achengzhao (审核中...)

前往app查看评论内容

#IL-23单抗#

III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性

2019-04-04

科室
- - 订阅+
  - 更多科室
工具
服务